Opus Genetics, Inc. SEC filings IRD
Opus Genetics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jun 17, 2005. Its latest annual report, Form ARS, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 21, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Mar 23, 2026 | Apr 20, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 12, 2026 | Apr 20, 2026 |
| DEFA14A | Additional proxy material | Apr 14, 2025 | — |
| DEFA14A | Additional proxy material | Apr 11, 2025 | — |
| DEFA14A | Additional proxy material | Apr 10, 2025 | — |
| DEFA14A | Additional proxy material | Apr 7, 2025 | — |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 11, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2024 | Jun 11, 2024 |
| DEF 14A | Proxy statement | May 1, 2023 | Jun 6, 2023 |
| DEFA14A | Additional proxy material | Jun 10, 2022 | — |
| DEFA14A | Additional proxy material | Jun 2, 2022 | — |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 13, 2022 |
| DEFA14A | Additional proxy material | Apr 26, 2021 | — |
| DEF 14A | Proxy statement | Apr 26, 2021 | Jun 7, 2021 |
| DEF 14A | Proxy statement | Apr 29, 2019 | Jun 6, 2019 |
| DEFA14A | Additional proxy material | Mar 11, 2019 | — |
| DEF 14A | Proxy statement | Feb 14, 2019 | Mar 26, 2019 |
| PRE 14A | Preliminary proxy statement | Feb 4, 2019 | Mar 26, 2019 |
| DEFA14A | Additional proxy material | Aug 22, 2018 | — |
| DEFA14A | Additional proxy material | Aug 9, 2018 | — |
| DEFA14A | Additional proxy material | Aug 7, 2018 | — |
| DEFA14A | Additional proxy material | Aug 7, 2018 | — |
| DEF 14A | Proxy statement | Jul 23, 2018 | Aug 30, 2018 |
| PRE 14A | Preliminary proxy statement | Jul 9, 2018 | Aug 30, 2018 |
| DEFA14A | Additional proxy material | Jun 28, 2018 | — |
| DEFA14A | Additional proxy material | Jun 18, 2018 | — |
| DEFA14A | Additional proxy material | Jun 14, 2018 | — |
| DEF 14A | Proxy statement | Apr 23, 2018 | Jun 14, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 6, 2018 | Jun 14, 2018 |
| DEF 14A | Proxy statement | Feb 24, 2017 | Apr 11, 2017 |
| PRE 14A | Preliminary proxy statement | Feb 13, 2017 | Apr 11, 2017 |
| DEF 14A | Proxy statement | Apr 18, 2016 | Jun 9, 2016 |
| DEFA14A | Additional proxy material | Apr 17, 2015 | — |
| DEF 14A | Proxy statement | Apr 14, 2015 | Jun 4, 2015 |
| PRE 14A | Preliminary proxy statement | Mar 30, 2015 | Jun 4, 2015 |
| DEF 14A | Proxy statement | Apr 18, 2014 | Jun 9, 2014 |
| PRE 14A | Preliminary proxy statement | Mar 28, 2014 | Jun 9, 2014 |
| DEF 14A | Proxy statement | Apr 22, 2013 | Jun 10, 2013 |
| DEF 14A | Proxy statement | Apr 26, 2012 | Jun 18, 2012 |
| DEF 14A | Proxy statement | Apr 26, 2011 | Jun 6, 2011 |
| DEFA14A | Additional proxy material | Apr 26, 2010 | — |
| DEF 14A | Proxy statement | Apr 26, 2010 | Jun 14, 2010 |
| DEF 14A | Proxy statement | Apr 20, 2009 | Jun 1, 2009 |
| DEF 14A | Proxy statement | Apr 29, 2008 | Jun 12, 2008 |
| DEF 14C | Information statement | Dec 11, 2007 | Dec 4, 2007 |
| PRE 14C | Rexahn pharmaceuticals pre 14c 11-20-2007 | Nov 21, 2007 | Nov 20, 2007 |
| DEF 14A | Proxy statement | May 16, 2007 | Jun 11, 2007 |
| DEF 14A | Proxy statement | May 15, 2006 | Jun 2, 2006 |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1228627
- Former names
- Ocuphire Pharma, Inc. (until Oct 22, 2024); REXAHN PHARMACEUTICALS, INC. (until Nov 9, 2020); CORPORATE ROAD SHOW DOT COM INC (until Apr 29, 2005); FERRARO FRANK (until Apr 29, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.